Ms. Parshall is a seasoned biotechnology leader with over 35 years in industry. An attorney by training, she spent over 30 years as the founding Chief Operating Officer of Ionis Pharmaceuticals and subsequently as a Strategic Advisor to the CEO, overseeing legal, finance, business development, portfolio management, strategic planning, manufacturing, regulatory, alliance management and other functions.
While at Ionis she was responsible for raising over $6 billion in financing from equity-based securities and corporate partner transactions. Ms. Parshall has sat on numerous public and private company Boards of Directors including, currently, Ionis Pharmaceuticals and Cytokinetics, two public biotechnology companies, and Ring Therapeutics and Repertoire Therapeutics, two private biotechnology companies. She was Chair of the Board of Akcea Therapeutics prior to its acquisition. Ms. Parshall has extensive Audit Committee and corporate governance experience.
Ms. Parshall received her BA manga cum laude from Harvard College and JD from Stanford University. Prior to working in industry, she was a partner at the Cooley law firm with a practice focusing on securities law and biotechnology corporate partnering.